On Flu Vaccine and the Elderly

Share this article:
Marc Siegel, MD
Marc Siegel, MD

I have written before about the flu vaccine and why I believe in it wholeheartedly yet do not believe it should be mandatory for health care workers. It is difficult for those in the media to grasp this grey area of medicine—useful, even essential, yet not mandatory. How can that be?

The answer is that the vaccine is effective, though not to the point of other vaccines such as measles, or hepatitis, or whooping cough, which are and should be mandatory in certain populations.

But the media is famous for not understanding the nuances of public health care. In fact, the latest news from the Centers for Disease Control, that this year's vaccine appears to be less than 60 percent effective at preventing severe flu symptoms, and only 9 percent with the elderly, has stirred the pot in the direction of denigrating what is still a useful vaccine.

For one thing, we know that the elderly have a diminished immune response, and especially in a year where a particularly nasty strain of the flu (which the vaccine covers) has hospitalized an almost unprecedented number of elderly patients, it makes sense to give those over 65 a second shot rather than no shot at all.

For another thing, if this flu vaccine is less effective in the elderly that's all the more reason for everyone around an older person to get vaccinated, creating a ring of immunity and decreasing the risk that flu will enter the house in the first place.

To be sure, we need to cut through the fear of flu vaccines, acknowledge their usefulness, and create newer, better ones. First, we need to widely adapt the cell culture flu vaccines that are catching on in Europe, to replace the antiquated hen-egg variety that still predominates here. Second, we need to plow ahead on research for a universal flu vaccine, targeting the M2 protein common to all flu. This vaccine, once successful, is likely to be one you can take once every ten years.

In the meantime, we need to promote compliance with the vaccine we do have; not over-touting it, but certainly not trashing it.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Is your marketing strategy stuck in 2005?

Is your marketing strategy stuck in 2005?

It is not enough to just have a killer black book or Rolodex. The market needs agile, swift marketing

Is guidance stifling social media?

Recent FDA draft guidance was meant to help companies create FDA-compliant tweets and handle third-party misinformation on the web. What other obstacles lie in the path of effective social media use?

FDA social media guides draw flak

FDA social media guides draw flak

Two FDA guidance documents on how health product manufacturers may participate in social media have drawn criticism from industry and consumer groups.